Meta-analysis: Evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 10, 2003, Pages 1247-1261

  Mathurin, P ^a   Raynard, B ^b   Dharancy, S ^a   Kirzin, S ^b   Fallik, D ^b   Pruvot, F R ^a   Roumilhac, D ^a   Canva, V ^a   Paris, J C ^a   Chaput, J C ^b   Naveau, S ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN C;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; META ANALYSIS; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037606042     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01580.x     Document Type: Article

References (82)

1. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
2. Mathurin P, Rixe O, Carbonel N, et al. Overview of medical treatments in hepatocdlular carcinoma: an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12: 111-26.
3. Simonetti RG, Liberati A, Anglioni C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-36.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2002; 37: 429-42.
5. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients; long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma with cirrhosis. N Engl J Med 1996; 334: 693-9.
7. Bruix J, Cirera I. Surgical resection and survival in western patients with hepatocellular carcinoma. J Hepatol 1992; 15: 350-5.
8. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-51.
9. Ringe B, Pichlmayr R, Wittekind C, Tussch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-85.
10. Bruix J, Sherman M, Llovet JM, et al. for the EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
11. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353-7.
12. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
13. Liovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
14. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-6.
15. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 77: 1792-6.
16. Castellano L, Calandra M, Del Vecchio Blanco C, de Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 1997; 27: 862-70.
17. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 1121-6.
18. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular cancer in Japan. Cancer 1994; 74: 2772-80.
19. Sacks HS, Berrier J, Reitman D, Angoma-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 19: 450-5.
20. Ozminkowski RJ, Wortman PM, Roloff DW. Inborn/outborn status and neonatal survival: a meta-analysis of non-randomized studies. Stat Med 1988; 7: 1207-21.
21. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
22. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of medlars and manual methods. Control Clin Trials 1985; 6: 271-9.
23. El-Serag H, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.
24. Liovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019-21.
25. Bruix J, Liovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
26. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-61.
27. Ono T, Yamanoi A, El Assal OM, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients. Cancer 2001; 91: 2378-85.
28. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 2000; 135: 1298-300.
29. Roseman BJ, Roh MS. Prognosis factors in surgical resection for hepatocellular carcinoma. Cancer Treat Res 1997; 90: 331-45.
30. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
31. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised controlled trial. Lancet 1999; 353: 797-801.
32. Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998; 83: 2302-11.
33. Bronowicki JP, Boudjema K, Chone L, Nisand G, Bazin C, Doffoel M. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 1996; 24: 293-300.
34. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 1618-24.
35. Poynard T. Evaluation de la qualité méthodologique des essais thérapeutiques randomisés. Presse Med 1988; 17: 315-8.
36. Demets DL. Methods of combining randomized clinical trials: strength and limitations. Stat Med 1987; 6: 341-8.
37. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
38. The San-In Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br J Surg 1997; 84: 1525-31.
39. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547-52.
40. Ziegler TR. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. J Parenter Enteral Nutr 1996; 20: 91-2.
41. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-7.
42. Kawata A, Une Y, Hosokawa M, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphocyte-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995; 18: 257-62.
43. Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M. Postoperative chemoimmu notherapy for the treatment of liver cancer. Semin Surg Oncol 1993; 9: 332-6.
44. Yoshida T, Sakon M, Umeshita K, et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol 2001; 32: 59-65.
45. Muto Y, Moriwaki H, Ninomya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
46. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-32.
47. Huang YH, Wu JC, Lui WY, et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000; 24: 551-5.
48. Hwang TL, Chen MF, Lee TY, Chen TJ, Lin DY, Liaw YF. Resection of hepatocellular carcinoma after transcatheter arterial embolization. Arrch Surg 1987; 122: 756-9.
49. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutics agents. Radiology 1987; 162: 345-51.
50. Stefanini GF, Foschi FG, Marsigli L, et al. Alpha-1 thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998; 45: 209-15.
51. Lygidakis NJ, Pothoulakis J, Konstantinidou A, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995; 15: 543-50.
52. Izumi R, Shimizu K, Miyazaki I. Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 1415-20.
53. Ikeda K, Saitoh S, Koida I, et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18: 204-10.
54. Lygidakis NJ, Tsiliakos S, Tallat A, Matsakis G, Tepetes K. Multidisciplinary management of hepatocellular carcinoma. Hepatogastroenterology 1997; 44: 268-73.
55. Tang ZY, Zhou HY, Zhao G, et al. Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother 1991; 8: 23-8.
56. Osaka Study Group on Hepatocellular Carcinoma. Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization treated patients with resectable or nonresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23(Suppl.): 29S-32S.
57. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy lot hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000; 231: 544-51.
58. Nakashima K, Kitano S, Kim YI, Aramaki M, Kawano K. Postoperative adjuvant arterial infusion chemotherapy for patients with hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 1410-4.
59. Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606-12.
60. Naomi T, Isshiki K, Katoh H, et al. The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg 1991; 213: 222-6.
61. Harada A, Nonami T, Kishimoto W, Nakao T, Tagaki H. Results of hepatic resection and postoperative arterial chemotherapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31: S35-7.
62. Monden M, Okamura J, Sakon M, et al. Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas. Cancer Chemother Pharmacol 1989; 23: S90-5.
63. Wu CC, Oho YZ, Lin Ho W, Wu TC, Liu TJ, Peng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-6.
64. Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellualar carcinoma. Jpn J Cancer Res 1996; 87: 206-11.
65. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 72: 3593-8.
66. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-703.
67. Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma. Ann Surg 1996; 224: 4-9.
68. Nagasue N, Galizia G, Kohno H, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma. A retrospective comparison of 138 liver resections. Surgery 1989; 106: 81-6.
69. Paye F, Jagot P, Vilgrain V, Farges O, Bode D, Belghiti J. Preoperative chemoembolization of hepatocellular carcinoma. Arch Surg 1998; 133: 767-72.
70. Uchida M, Khono H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20: 326-31.
71. Imaoka S, Sasaki Y, Shibata T, et al. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23: S126-8.
72. Izumi R, Shimizu S, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295-301.
73. Li JO, Zhang YK, Zhang WZ, Yuan YF, Li GH. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 1995; 121: 364-6.
74. Ueno S, Tanabe G, Yoshida A, Yoshidome S, Takao S, Aikou T. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999; 86: 248-54.
75. Takenaka K, Yoshida K, Nishizaki T, et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocelllular carcinoma. Am J Surg 1995; 169: 400-5.
76. Tanaka K, Shimada H, Togo S, et al. Use of transcatheter arterial infusion of anti-cancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 1999; 46: 1083-8.
77. Asahara T, Itamoto T, Katayama K, et al. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma - results of long-term follow-up. Hepatogastroenterology 1999; 46: 1042-8.
78. Yamamoto M, Arii S, Sughara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996; 83: 336-40.
79. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183-8.
80. Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997; 24(2 Suppl, 6): S6-18, S6-25.
81. Khono H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43: 1405-9.
82. Poynard T, Munteanu M, Ratziu V, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002; 136: 888-95.